A patent protecting AstraZeneca's Pulmicort Respules asthma drug in the U.S. was deemed invalid on Tuesday, paving the way for a generic version of the drug to hit store shelves.
http://www.foxbusiness.com/industries/2013/04/02/astrazeneca-faces-new-drug-patent-setback-in-us/
http://www.foxbusiness.com/industries/2013/04/02/astrazeneca-faces-new-drug-patent-setback-in-us/
No comments:
Post a Comment